GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow +6.6% ·
net new positions +7.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | -4 | 40.74M | $985.15M | +4 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | n/a |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | n/a |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | n/a |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | n/a |
| Q2 2024 | 7 | n/a | 8.29M | $30.99M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.33M | -4.8% | $28.53M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 2 | BlackRock ✦ (passive) | 3.85M | n/a | $17.35M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 3.14M | n/a | $14.16M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 2.29M | n/a | $10.32M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | AQR Capital Management ✦ | 1.28M | +459.4% | $5.79M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 6 | Geode Capital Management ✦ (passive) | 1.12M | +12.0% | $5.07M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 831.82K | +3.8% | $3.75M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 615.10K | +274.8% | $2.77M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Marshall Wace ✦ | 446.08K | +20.0% | $2.01M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 239.94K | +7.5% | $1.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 224.82K | +19.8% | $1.01M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 12 | Citadel Advisors ✦ | 77.92K | New | $351,411 | 0.0% | New | 1 | SEC ↗ ×2 |
| 13 | Millennium Management ✦ | 64.63K | -80.4% | $291,486 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $351,411 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13 sh · $137
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.9% of class · View original SEC filing ↗